49 results about "Delirium" patented technology

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

The disclosed apparatus, systems and methods relate to predicting, screening, and monitoring for delirium. Systems and methods may include receiving one or more signals from one or more sensing devices; processing the one or more signals to extract one or more features from the one or more signals; analyzing the one or more features to determine one or more values for each of the one or more features; comparing at least one of the one or more values or a measure based on at least one of the one or more values to a threshold; determining a presence, absence, or likelihood of the subsequent development of delirium for a patient based on the comparison; and outputting an indication of the presence, absence, or likelihood of the subsequent development of delirium for the patient.

The present invention relates to novel compounds of formula (I) useful as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions for the prevention or therapeutic improvement of memory dysfunction, sleep and wakefulness disorders, anxiety, depression, mood disorders, seizures, obesity, diabetes, appetite and food intake Abnormalities, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorder (including bulimia), anorexia, psychosis (including manic depression), schizophrenia, delirium, dementia, catatonia, cognitive impairment , attention deficit disorder, substance use disorder, movement disorders (including Parkinson's disease), epilepsy, and addiction.

This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for treating delirium in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.

The present invention relates to a monitoring system (1, 2, 3) and a corresponding monitoring method for monitoring a patient and detecting delirium of the patient in an unobtrusive manner without the need of on-body sensors. The proposed monitoring system comprises a monitoring unit (10) for obtaining image data (30) of the patient over time, an image analysis unit (12) for detecting motion events of the patient from the obtained image data (30), an evaluation unit (14) for classifying the detected motion events into delirium-typical motion events and non-delirium-typical motion events, and a delirium determination unit (16) for determining a delirium score (32) from the duration, intensity, type, location and / or occurrence of delirium-typical motion events, said delirium score (32) indicating the likelihood and / or strength of delirium of the patient.

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

The invention relates to a medicinal injection for treating delirium and a preparation method thereof, and relates to application of poloxamer to the preparation of refreshment calming injections. The medicinal injection is processed by using 7.5 parts of musk, 30 parts of turmeric root-tuber, 1 part of borneol, 30 parts of bupleurum, gardenia and 1 to 200 parts of poloxamer serving as a solubilizer.

The invention discloses a drug for treating psychosis. The drug is finely prepared from the following crude drugs in parts by weight: 2-6 parts of bile arisaema, 2-5 parts of scorpion, 2-8 parts of antelope horns, 5-12 parts of rhubarb, 3-10 parts of senna leaves, 5-20 parts of compounds of glauber-salt and liquorice, 5-8 parts of acorus calamus, 0.5-1.5 parts of cinnabaris, 5-8 parts of nacre, 3-10 parts of juncus effuses, 2-10 parts of Chinese eaglewood, 1-6 parts of alum, 2-10 parts of gleditsia sinensis, 10-20 parts of fructus trichosanthis, 3-15 parts of radix curcumae, 6-15 parts of rhizoma cyperi, 3-15 parts of polygala tenuifolia, 10-20 parts of poria with hostwood, 5-15 parts of date seeds, 3-10 parts of scutellaria baicalensis and 10-15 parts of radix ophiopogonis. The drug has the effects on clearing phlegm and resuscitating, refreshing and clearing away the heart fire, eliminating convulsions and arresting convulsion, smoothing the liver and regulating vital energy, eliminating delirium and calming the nerves as well as clearing away heat and purging pathogenic fire. Compared with the prior art, the drug has the advantages of short course of treatment, high effect taking speed, high cure rate, no easiness for recurrence, no toxic or side effect, low cost, easiness for patients to accept, and the like.